Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
Heart failure (HF) is a common disease in which the heart cannot meet the metabolic demands of the body. It mostly occurs in individuals 65 years or older. Cardiac transplantation is the best option for patients with advanced HF. High numbers of patient-specific cardiac myocytes (CMs) can be generat...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Animals |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2615/10/9/1561 |
id |
doaj-eebeb1797e7c460abc535efb1240fdd1 |
---|---|
record_format |
Article |
spelling |
doaj-eebeb1797e7c460abc535efb1240fdd12020-11-25T02:45:45ZengMDPI AGAnimals2076-26152020-09-01101561156110.3390/ani10091561Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal ModelsAlexandra Bizy0Matthew Klos1Department of Biomedical Sciences, Faculty of Health Sciences, Universidad CEU Cardenal Herrera, CEU Universities, Moncada, 46113 Valencia, SpainPediatric Cardiac and Thoracic Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USAHeart failure (HF) is a common disease in which the heart cannot meet the metabolic demands of the body. It mostly occurs in individuals 65 years or older. Cardiac transplantation is the best option for patients with advanced HF. High numbers of patient-specific cardiac myocytes (CMs) can be generated from induced pluripotent stem cells (iPSCs) and can possibly be used to treat HF. While some studies found iPSC-CMS can couple efficiently to the damaged heart and restore cardiac contractility, almost all found iPSC-CM transplantation is arrhythmogenic, thus hampering the use of iPSC-CMs for cardiac regeneration. Studies show that iPSC-CM cultures are highly heterogeneous containing atrial-, ventricular- and nodal-like CMs. Furthermore, they have an immature phenotype, resembling more fetal than adult CMs. There is an urgent need to overcome these issues. To this end, a novel and interesting avenue to increase CM maturation consists of modulating their metabolism. Combined with careful engineering and animal models of HF, iPSC-CMs can be assessed for their potential for cardiac regeneration and a cure for HF.https://www.mdpi.com/2076-2615/10/9/1561heart failurecardiac regenerationiPSC-CMsmetabolism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexandra Bizy Matthew Klos |
spellingShingle |
Alexandra Bizy Matthew Klos Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models Animals heart failure cardiac regeneration iPSC-CMs metabolism |
author_facet |
Alexandra Bizy Matthew Klos |
author_sort |
Alexandra Bizy |
title |
Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models |
title_short |
Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models |
title_full |
Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models |
title_fullStr |
Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models |
title_full_unstemmed |
Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models |
title_sort |
optimizing the use of ipsc-cms for cardiac regeneration in animal models |
publisher |
MDPI AG |
series |
Animals |
issn |
2076-2615 |
publishDate |
2020-09-01 |
description |
Heart failure (HF) is a common disease in which the heart cannot meet the metabolic demands of the body. It mostly occurs in individuals 65 years or older. Cardiac transplantation is the best option for patients with advanced HF. High numbers of patient-specific cardiac myocytes (CMs) can be generated from induced pluripotent stem cells (iPSCs) and can possibly be used to treat HF. While some studies found iPSC-CMS can couple efficiently to the damaged heart and restore cardiac contractility, almost all found iPSC-CM transplantation is arrhythmogenic, thus hampering the use of iPSC-CMs for cardiac regeneration. Studies show that iPSC-CM cultures are highly heterogeneous containing atrial-, ventricular- and nodal-like CMs. Furthermore, they have an immature phenotype, resembling more fetal than adult CMs. There is an urgent need to overcome these issues. To this end, a novel and interesting avenue to increase CM maturation consists of modulating their metabolism. Combined with careful engineering and animal models of HF, iPSC-CMs can be assessed for their potential for cardiac regeneration and a cure for HF. |
topic |
heart failure cardiac regeneration iPSC-CMs metabolism |
url |
https://www.mdpi.com/2076-2615/10/9/1561 |
work_keys_str_mv |
AT alexandrabizy optimizingtheuseofipsccmsforcardiacregenerationinanimalmodels AT matthewklos optimizingtheuseofipsccmsforcardiacregenerationinanimalmodels |
_version_ |
1724760600880349184 |